Gapping down
In reaction to disappointing earnings/guidance: SGOC -27.2%, BV -12.8% (also announced that effective Jan. 31, 2014, Stephen Collins will step down as CEO), VVTV -8.6%, LQDT -6.9%, DLTR -6.7%, TGT -3.7%, ANF -3.4%, LTD -3.3%.
Other news: FU -12.5% (continued weakness), QLTI -9.3% (announces oral retinoid program clinical and regulatory update, and review of strategic alternatives), FOLD -8.5% (Amicus Therapeutics and GSK announce revised Fabry agreement; also downgraded by multiple analysts), VJET -8.2% (continued weakness following Citron mention), ATTU -6.7% (priced its public offering of 2.48 mln ordinary shares at a price to the public of $7.00/share), GFI -6.4% (still checking), AL -5.2% ( announces secondary public offering of ~10.14 mln shares of common stock), WBMD -3.7% (announces $300 mln offering of convertible notes due 2020), ZHNE -3% (modestly pulling back from yesterday's Craig Hallum boost), DG -2.3% (on DLTR results), AU -2.1% (still checking), ABEV -2.1% (still checking), ARRY -1.5% (announces that Kevin Koch, President and Chief Scientific Officer, will be leaving Array to pursue other opportunities), SI -1.1% (still checking), FDO -1% (on DLTR results).
Analyst comments: TRN -1.9% (downgraded to Underperform from Outperform at Raymond James), PM -0.8% (downgraded to Neutral from Buy at Goldman; removed from Conviction Buy list ), QSII -0.4% (initiated with a Sell at Deutsche Bank).